Oncolytics' Reolysin reduces lung cancer tumors in trial

02/11/2013 | Reuters

Oncolytics Biotech's experimental drug Reolysin, in combination with carboplatin and paclitaxel, was associated with the shrinking of tumors in 95% of patients with metastatic or recurrent squamous cell carcinoma of the lung during a Phase II trial. "Based on these findings we intend to continue to look at Reolysin as a treatment for cancers of the lung and cancers that metastasize to the lung," CEO Brad Thompson said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX